At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 790 enrolled
Drug / intervention
VYD222 (pemivibart) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Study to Evaluate the Efficacy and Safety of VYD222 for Prevention of COVID-19 (CANOPY)
In Brief
A Phase 3 clinical trial evaluating VYD222 (pemivibart) and Normal saline for COVID-19 and SARS-CoV-2. Completed, enrolled 790 participants across 18 sites.
Detailed Summary
A study to investigate the prevention of COVID-19 with VYD222 in adults with immune compromise and in participants aged 12 years or older who are at risk of exposure to SARS-CoV-2
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID-19, SARS-CoV-2
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
202420252026
Enrollment StartSep 2023
First PostedSep 2023
Primary CompletionNov 2024
TodayJul 2026
First PostedSep 15, 2023
Enrollment StartSep 8, 2023
Primary CompletionNov 19, 2024
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 2.8 years ago
Interventions
VYD222 (pemivibart)drug
Participants will be dosed on Day 1 followed by redosing at Month 3 (approximately 90 days) with VYD222.
Normal salinedrug
Participants will be dosed on Day 1 followed by redosing at Month 3 (approximately 90 days) with Placebo.